Jul. 1 at 2:14 PM
$ACHV We finally have a competent CEO and management team. I personally liked Bencich, I thought he was more transparent than most -- almost to a fault - but I never understood the need for the Sopharma facility as it seemed like a massive risk particularly when Trump was elected.
Look at
$UNCY -- received a CRL yesterday because its CEO stuck with an Indian facility that was previously deemed to have manufacturing deficits. The FDA didn't even bother to inspect the facility in India again before issuing a blind-side rejection -- clearly their move should have been to move operations to the USA, like Achieve's CEO did.
I don't love the probability of a zero-bid contract to Adare based on BoD connections, but that's the business world we operate in today where nobody bats an eye. As long as the FDA is okay with Adare, I am fine if the contract is a bit less advantageous to us than it could have been with an open RFP campaign for a new manufacturer.
